According to a new report, published by KBV research, The Global Plasma Protein Therapeutics Market size is expected to reach $39.1 billion by 2029, rising at a market growth of 5.5% CAGR during the forecast period.
The Hospitals segment acquired maximum revenue share in the Global Plasma Protein Therapeutics Market by End User in 2022 thereby, achieving a market value of $29.3 billion by 2029. The prevalence of infectious and chronic disorders, like immunodeficiency disorder or hemophilia, is on the rise, and public and private organizations are taking steps to develop the healthcare industry, which is causing the segment to grow at a substantial rate. In addition, more and more modern medical equipment and technology are being integrated into hospitals as well as being changed into hospitals.
The Albumin segment is showcasing a CAGR of 5.8% during (2023 - 2029). Due to the increasing popularity of high-quality treatment methods, the segment's dominance is anticipated to last during the projection period. The segment is expanding due to a growing emphasis on developing new treatments for infectious diseases as well as the complications of real-time applications. The primary plasma protein, albumin, is responsible for several vital processes, including controlling blood volume.
The Hemophilia segment is leading the Global Plasma Protein Therapeutics Market by Application in 2022 thereby, achieving a market value of $22 billion by 2029. Having hemophilia, a rare inherited bleeding illness, makes it difficult for the blood to clot normally. Uncontrolled bleeding, which commonly takes place in different parts of the body, is the primary sign of this illness. The degree of hemophilia affects the amount of bleeding. As more patients are diagnosed with hemophilia, the market is anticipated to expand in the coming years.
The North America market dominated the Global Plasma Protein Therapeutics Market by Region in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $16.2 billion by 2029. The Europe market is exhibiting a CAGR of 5.1% during (2023 - 2029). Additionally, The Asia Pacific market would display a CAGR of 6.6% during (2023 - 2029).
Full Report: https://www.kbvresearch.com/plasma-protein-therapeutics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country-wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Bayer AG, Abeona Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Grifols, S.A., Baxter International, Inc., Kedrion S.p.A, Octapharma AG, CSL Limited (CSL Behring), Taibang Biological Group Co., Ltd and ADMA Biologics, Inc.
By End User
By Product Type
By Application
By Geography
Companies Profiled
Unique Offerings 
